Involvement of cytochrome P450 3A4 and P-glycoprotein in first-pass intestinal extraction of omeprazole in rabbits

Acta Pharmacologica Sinica

Volumn 30, Issue 11, 2009, Pages 1566-1572

  Fang, Hai Ming ^a   Xu, Jian Ming ^a   Mei, Qiao ^a   Diao, Lei ^a   Chen, Mo Li ^a   Jin, Juan ^a   Xu, Xin Hua ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Cytochrome P450 3A4; Intestinal first pass extraction; Ketoconazole; Omeprazole; P glycoprotein; Pharmacokinetics; Verapamil

Indexed keywords

CYTOCHROME P450 3A4; GLYCOPROTEIN P; KETOCONAZOLE; OMEPRAZOLE; VERAPAMIL;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG HALF LIFE; FIRST PASS EFFECT; IN VIVO STUDY; INTESTINE; LIVER; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; RABBIT; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ANIMALS; ANTI-ULCER AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CYTOCHROME P-450 CYP3A; DOSE-RESPONSE RELATIONSHIP, DRUG; INJECTIONS, INTRAVENOUS; INTESTINE, SMALL; LIVER; MALE; OMEPRAZOLE; P-GLYCOPROTEIN; RABBITS;

EID: 70449344458     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2009.142     Document Type: Article

References (22)

1. Kaminsky LS, Zhang QY. The small intestine as a xenobioticmetabolizing organ. Drug Metab Dispos 2003; 31: 1520-52
2. Glaeser H, Drescher S, Hofmann U, Heinkele G, Somogyi AA, Eichelbaum M, et al. Impact of concentration and rate of intraluminal drug delivery on absorption and gut wall metabolism of verapamil in humans. Clin Pharmacol Ther 2004; 76: 230-238
3. Blum RA. Lansoprazole and omeprazole in the treatment of acid peptic disorders. AmJ Health Syst Pharm 1996; 53: 1401-1415
4. Robinson M, Horn J. Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know. Drugs 2003; 63: 2739-2754
5. Kunta JR, Lee SH, Perry BA, Lee YH, Sinko PJ. Differentiation of gut and hepatic first-pass loss of verapamil in intestinal and vascular access-ported (IVAP) rabbits. Drug Metab Dispos 2004; 32: 1293-1298
6. Hoffman DJ, Seifert T, Borre A, Nellans HN. Method to estimate the rate and extent of intestinal absorption in conscious rats using an absorption probe and portal blood sampling. Pharm Res 1995; 12: 889-894
7. Tam-Zaman N, Tam YK, Tawfik S, Wiltshire H. Factors responsible for the variability of saquinavir absorption: studies using an instrumented dog model. Pharm Res 2004; 21: 436-442
8. Ward KW, Stelman GJ, Morgan JA, Zeigler KS, Azzarano LM, Kehler JR, et al. Development of an in vivo preclinical screen model to estimate absorption and first-pass hepatic extraction of xenobiotics. II. Use of ketoconazole to identify P-glycoprotein/CYP3A-limited bioavailability in the monkey. Drug Metab Dispos 2004; 32: 172-177
9. Kunta JR, Sinko PJ. Intestinal drug transporters: in vivo function and clinical importance. Curr Drug Metab 2004; 5: 109-124
10. Chan LM, Lowes S, Hirst BH. The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. Eur J Pharm Sci 2004; 21: 25-51.
11. Sutyak JP, Lee YH, Perry BA, Stern W, Makhey V, Sinko PJ. Improved longevity and functionality of a canine model providing portal vein and multi-site intestinal access. Comp Med 2000; 50: 167-174
12. Kunta JR, Perry BA, Sutyak JP, Sinko PJ. Development of a novel intestinal and vascular access port (IVAP) rabbit model to study regiospecific oral absorption pharmacokinetics. Comp Med 2001; 51: 349-356
13. Hu XP, Xu JM, Hu YM, Mei Q, Xu XH. Effects of CYP2C19 genetic polymorphism on the pharmacokinetics and pharmacodynamics of OME in Chinese people. J Clin Pharm Ther 2007; 32: 517-524
14. Lee YH, Perry BA, Lee HS, Kunta JR, Sutyak JP, Sinko PJ. Differentiation of gut and hepatic first-pass effect of drugs: 1. Studies of verapamil in ported dogs. Pharm Res 2001; 18: 1721-1728
15. Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res 1993; 10: 1093-1095
16. Paine MF, Hart HL, Ludington SS, Haining RL, Rettie AE, Zeldin DC. The human intestinal cytochrome P450 "pie". Drug Metab Dispos 2006; 34: 880-886
17. Adachi Y, Suzuki H, Sugiyama Y. Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res 2001; 18: 1660-1668
18. Yamazaki M, Neway WE, Ohe T, Chen IW, Rowe JF, Hochman JH, et al. In vitro substrate identification studies for P-glycoprotein-mediated transport: species difference and predictability of in vivo results. J Pharmacol Exp Ther 2001; 296: 723-735
19. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, et al. Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther 2001; 299: 620-628
20. Schuetz EG, Umbenhauer DR, Yasuda K, Brimer C, Nguyen L, Relling MV, et al. Altered expression of hepatic cytochromes P-450 in mice deficient in one or more mdr1 genes. Mol Pharmacol 2000; 57: 188-197
21. Cousein E, Barthélémy C, Poullain S, Simon N, Lestavel S, Williame V, et al. P-glycoprotein and cytochrome P450 3A4 involvement in risperidone transport using an in vitro Caco-2/TC7 model and an in vivo model. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 878-886
22. Uno T, Niioka T, Hayakari M, Yasui-Furukori N, Sugawara K, Tateishi T. Absolute bioavailability and metabolism of omeprazole in relation to CYP2C19 genotypes following single intravenous and oral administrations. Eur J Clin Pharmacol 2007; 63: 143-149